$2.94 Billion is the total value of PFM Health Sciences, LP's 71 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | ADAPTIMMUNE THERAPEUTICS PLCcall | $0 | – | -291,800 | -100.0% | -0.04% | – | |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -188,243 | -100.0% | -0.06% | – |
| BYSI | Exit | BEYONDSPRING INC | $0 | – | -161,697 | -100.0% | -0.08% | – |
| Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -15,000 | -100.0% | -0.08% | – | |
| VECT | Exit | VECTIVBIO HLDG AG | $0 | – | -544,706 | -100.0% | -0.12% | – |
| CERT | Exit | CERTARA INC | $0 | – | -143,028 | -100.0% | -0.14% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -16,900 | -100.0% | -0.14% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -143,297 | -100.0% | -0.14% | – |
| LFST | Exit | LIFESTANCE HEALTH GROUP INC | $0 | – | -443,595 | -100.0% | -0.19% | – |
| Exit | NOVAVAX INCnote 3.750% 2/0 | $0 | – | -4,250,000 | -100.0% | -0.22% | – | |
| Exit | HUMANA INCcall | $0 | – | -21,000 | -100.0% | -0.24% | – | |
| FSII | Exit | FS DEVELOPMENT CORP II | $0 | – | -1,000,000 | -100.0% | -0.29% | – |
| Exit | DYNAVAX TECHNOLOGIES CORPcall | $0 | – | -521,800 | -100.0% | -0.30% | – | |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -99,375 | -100.0% | -0.31% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -84,455 | -100.0% | -0.31% | – |
| AVIR | Exit | ATEA PHARMACEUTICALS INC | $0 | – | -302,532 | -100.0% | -0.31% | – |
| Exit | SIGHT SCIENCES INC | $0 | – | -483,538 | -100.0% | -0.32% | – | |
| Exit | STEVANATO GROUP S P A | $0 | – | -549,002 | -100.0% | -0.41% | – | |
| ALLO | Exit | ALLOGENE THERAPEUTICS INC | $0 | – | -775,819 | -100.0% | -0.59% | – |
| Exit | IONIS PHARMACEUTICALS INCnote 0.125%12/1 | $0 | – | -23,000,000 | -100.0% | -0.62% | – | |
| Exit | NEUROCRINE BIOSCIENCES INCcall | $0 | – | -261,500 | -100.0% | -0.74% | – | |
| Exit | BRISTOL-MYERS SQUIBB COcall | $0 | – | -612,000 | -100.0% | -1.06% | – | |
| Exit | HORIZON THERAPEUTICS PUB Lcall | $0 | – | -439,400 | -100.0% | -1.42% | – | |
| Exit | SELECT SECTOR SPDR TRcall | $0 | – | -1,602,200 | -100.0% | -1.77% | – | |
| Exit | UNITEDHEALTH GROUP INCcall | $0 | – | -157,200 | -100.0% | -1.81% | – | |
| Exit | GILEAD SCIENCES INCcall | $0 | – | -963,700 | -100.0% | -1.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.